Company / Shareholders' Equity
SUTRO BIOPHARMA, INC. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$44.6M
FY2025
5-year range
$44.6M / $332.0M
FY2021-FY2025
Trend
-70.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $332M in FY2022 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -19.5%.
Declined from $253M to $45M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -48.8%
- 5-Year CAGR
- -19.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- SUTRO BIOPHARMA, INC.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -19.5%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 70.2% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.6M | -70.2% |
| FY2024 | $149.6M | -40.7% |
| FY2023 | $252.6M | -23.9% |
| FY2022 | $332.0M | +239.6% |
| FY2021 | $97.8M | -25.7% |
| FY2020 | $131.5M | +220.7% |
| FY2019 | -$109.0M | -19.9% |
| FY2018 | -$90.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026